vs
Essex Property Trust（ESS）与Indivior Pharmaceuticals, Inc.（INDV）财务数据对比。点击上方公司名可切换其他公司
Essex Property Trust的季度营收约是Indivior Pharmaceuticals, Inc.的1.3倍（$479.6M vs $357.0M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs 17.9%，领先11.0%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
ESS vs INDV — 直观对比
营收规模更大
ESS
是对方的1.3倍
$357.0M
净利率更高
INDV
高出11.0%
17.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $357.0M |
| 净利润 | $85.7M | $103.0M |
| 毛利率 | 70.0% | 82.1% |
| 营业利润率 | 31.7% | 22.7% |
| 净利率 | 17.9% | 28.9% |
| 营收同比 | 5.5% | — |
| 净利润同比 | -71.6% | 390.5% |
| 每股收益（稀释后） | $1.24 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSINDV
| Q4 25 | $479.6M | $357.0M | ||
| Q3 25 | $473.3M | $314.0M | ||
| Q2 25 | $469.8M | $302.0M | ||
| Q1 25 | $464.6M | $266.0M | ||
| Q4 24 | $454.5M | — | ||
| Q3 24 | $450.7M | $307.0M | ||
| Q2 24 | $442.4M | $299.0M | ||
| Q1 24 | $426.9M | — |
净利润ESSINDV
| Q4 25 | $85.7M | $103.0M | ||
| Q3 25 | $172.7M | $42.0M | ||
| Q2 25 | $231.5M | $18.0M | ||
| Q1 25 | $212.8M | $47.0M | ||
| Q4 24 | $301.7M | — | ||
| Q3 24 | $125.5M | $22.0M | ||
| Q2 24 | $99.0M | $-97.0M | ||
| Q1 24 | $285.1M | — |
毛利率ESSINDV
| Q4 25 | 70.0% | 82.1% | ||
| Q3 25 | 69.2% | 73.2% | ||
| Q2 25 | 70.7% | 82.8% | ||
| Q1 25 | 69.6% | 83.1% | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.5% | 78.5% | ||
| Q2 24 | 70.8% | 73.6% | ||
| Q1 24 | 69.7% | — |
营业利润率ESSINDV
| Q4 25 | 31.7% | 22.7% | ||
| Q3 25 | 44.5% | 13.7% | ||
| Q2 25 | 59.5% | 23.8% | ||
| Q1 25 | 55.3% | 24.8% | ||
| Q4 24 | 67.0% | — | ||
| Q3 24 | 28.6% | 11.4% | ||
| Q2 24 | 31.1% | -39.5% | ||
| Q1 24 | 31.0% | — |
净利率ESSINDV
| Q4 25 | 17.9% | 28.9% | ||
| Q3 25 | 36.5% | 13.4% | ||
| Q2 25 | 49.3% | 6.0% | ||
| Q1 25 | 45.8% | 17.7% | ||
| Q4 24 | 66.4% | — | ||
| Q3 24 | 27.8% | 7.2% | ||
| Q2 24 | 22.4% | -32.4% | ||
| Q1 24 | 66.8% | — |
每股收益（稀释后）ESSINDV
| Q4 25 | $1.24 | $0.79 | ||
| Q3 25 | $2.56 | $0.33 | ||
| Q2 25 | $3.44 | $0.14 | ||
| Q1 25 | $3.16 | $0.38 | ||
| Q4 24 | $4.00 | — | ||
| Q3 24 | $1.84 | $0.16 | ||
| Q2 24 | $1.45 | $-0.72 | ||
| Q1 24 | $4.25 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | $195.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.5B | $-98.0M |
| 总资产 | $13.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESSINDV
| Q4 25 | $76.2M | $195.0M | ||
| Q3 25 | $66.0M | $445.0M | ||
| Q2 25 | $58.7M | $510.0M | ||
| Q1 25 | $98.7M | $373.0M | ||
| Q4 24 | $66.8M | — | ||
| Q3 24 | $71.3M | — | ||
| Q2 24 | $55.2M | — | ||
| Q1 24 | $499.0M | — |
总债务ESSINDV
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
股东权益ESSINDV
| Q4 25 | $5.5B | $-98.0M | ||
| Q3 25 | $5.6B | $-207.0M | ||
| Q2 25 | $5.6B | $-257.0M | ||
| Q1 25 | $5.6B | $-285.0M | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.4B | $-310.0M | ||
| Q2 24 | $5.5B | $-281.0M | ||
| Q1 24 | $5.5B | — |
总资产ESSINDV
| Q4 25 | $13.2B | $1.2B | ||
| Q3 25 | $13.2B | $1.4B | ||
| Q2 25 | $13.2B | $1.5B | ||
| Q1 25 | $13.2B | $1.4B | ||
| Q4 24 | $12.9B | — | ||
| Q3 24 | $12.6B | — | ||
| Q2 24 | $12.5B | — | ||
| Q1 24 | $12.9B | — |
负债/权益比ESSINDV
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $-221.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-245.0M |
| 自由现金流率自由现金流/营收 | — | -68.6% |
| 资本支出强度资本支出/营收 | — | 6.7% |
| 现金转化率经营现金流/净利润 | 12.53× | -2.15× |
| 过去12个月自由现金流最近4个季度 | — | $-93.0M |
8季度趋势，按日历期对齐
经营现金流ESSINDV
| Q4 25 | $1.1B | $-221.0M | ||
| Q3 25 | $342.6M | $-39.0M | ||
| Q2 25 | $216.1M | $158.0M | ||
| Q1 25 | $281.5M | $75.0M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $316.2M | $2.0M | ||
| Q2 24 | $218.9M | $88.0M | ||
| Q1 24 | $314.9M | — |
自由现金流ESSINDV
| Q4 25 | — | $-245.0M | ||
| Q3 25 | — | $-59.0M | ||
| Q2 25 | — | $141.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | — | $84.0M | ||
| Q1 24 | — | — |
自由现金流率ESSINDV
| Q4 25 | — | -68.6% | ||
| Q3 25 | — | -18.8% | ||
| Q2 25 | — | 46.7% | ||
| Q1 25 | — | 26.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | 28.1% | ||
| Q1 24 | — | — |
资本支出强度ESSINDV
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率ESSINDV
| Q4 25 | 12.53× | -2.15× | ||
| Q3 25 | 1.98× | -0.93× | ||
| Q2 25 | 0.93× | 8.78× | ||
| Q1 25 | 1.32× | 1.60× | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 2.52× | 0.09× | ||
| Q2 24 | 2.21× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
